JP2025163031A5 - - Google Patents

Info

Publication number
JP2025163031A5
JP2025163031A5 JP2025113783A JP2025113783A JP2025163031A5 JP 2025163031 A5 JP2025163031 A5 JP 2025163031A5 JP 2025113783 A JP2025113783 A JP 2025113783A JP 2025113783 A JP2025113783 A JP 2025113783A JP 2025163031 A5 JP2025163031 A5 JP 2025163031A5
Authority
JP
Japan
Prior art keywords
seq
liposome
amino acid
acid sequence
helper
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2025113783A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025163031A (ja
Filing date
Publication date
Priority claimed from PCT/US2018/057286 external-priority patent/WO2019084118A2/en
Application filed filed Critical
Publication of JP2025163031A publication Critical patent/JP2025163031A/ja
Publication of JP2025163031A5 publication Critical patent/JP2025163031A5/ja
Pending legal-status Critical Current

Links

JP2025113783A 2017-10-25 2025-07-04 リン酸化タウペプチドの組成物およびその使用 Pending JP2025163031A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762577157P 2017-10-25 2017-10-25
US62/577,157 2017-10-25
PCT/US2018/057286 WO2019084118A2 (en) 2017-10-25 2018-10-24 PHOSPHORYLATED TUBE PEPTIDE COMPOSITIONS AND USES THEREOF
JP2020523284A JP7550643B2 (ja) 2017-10-25 2018-10-24 リン酸化タウペプチドの組成物およびその使用
JP2023018374A JP7793562B2 (ja) 2017-10-25 2023-02-09 リン酸化タウペプチドの組成物およびその使用

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2023018374A Division JP7793562B2 (ja) 2017-10-25 2023-02-09 リン酸化タウペプチドの組成物およびその使用

Publications (2)

Publication Number Publication Date
JP2025163031A JP2025163031A (ja) 2025-10-28
JP2025163031A5 true JP2025163031A5 (cg-RX-API-DMAC7.html) 2026-02-24

Family

ID=64362628

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2020523284A Active JP7550643B2 (ja) 2017-10-25 2018-10-24 リン酸化タウペプチドの組成物およびその使用
JP2023018374A Active JP7793562B2 (ja) 2017-10-25 2023-02-09 リン酸化タウペプチドの組成物およびその使用
JP2025113783A Pending JP2025163031A (ja) 2017-10-25 2025-07-04 リン酸化タウペプチドの組成物およびその使用

Family Applications Before (2)

Application Number Title Priority Date Filing Date
JP2020523284A Active JP7550643B2 (ja) 2017-10-25 2018-10-24 リン酸化タウペプチドの組成物およびその使用
JP2023018374A Active JP7793562B2 (ja) 2017-10-25 2023-02-09 リン酸化タウペプチドの組成物およびその使用

Country Status (25)

Country Link
US (4) US11124552B2 (cg-RX-API-DMAC7.html)
EP (1) EP3700556A2 (cg-RX-API-DMAC7.html)
JP (3) JP7550643B2 (cg-RX-API-DMAC7.html)
KR (2) KR20240145065A (cg-RX-API-DMAC7.html)
CN (2) CN117298259A (cg-RX-API-DMAC7.html)
AR (1) AR113792A1 (cg-RX-API-DMAC7.html)
AU (2) AU2018355325B2 (cg-RX-API-DMAC7.html)
BR (1) BR112020008168A2 (cg-RX-API-DMAC7.html)
CA (2) CA3079423A1 (cg-RX-API-DMAC7.html)
CL (2) CL2020001070A1 (cg-RX-API-DMAC7.html)
CO (1) CO2020006073A2 (cg-RX-API-DMAC7.html)
CR (1) CR20240219A (cg-RX-API-DMAC7.html)
DO (1) DOP2020000135A (cg-RX-API-DMAC7.html)
EA (1) EA202091012A1 (cg-RX-API-DMAC7.html)
EC (1) ECSP20026986A (cg-RX-API-DMAC7.html)
IL (2) IL302108A (cg-RX-API-DMAC7.html)
JO (1) JOP20200103A1 (cg-RX-API-DMAC7.html)
MA (1) MA50465A (cg-RX-API-DMAC7.html)
MX (2) MX2020004338A (cg-RX-API-DMAC7.html)
MY (1) MY202233A (cg-RX-API-DMAC7.html)
PH (1) PH12020550432A1 (cg-RX-API-DMAC7.html)
SA (1) SA520411820B1 (cg-RX-API-DMAC7.html)
SG (1) SG11202003556UA (cg-RX-API-DMAC7.html)
TW (2) TW202333768A (cg-RX-API-DMAC7.html)
WO (1) WO2019084118A2 (cg-RX-API-DMAC7.html)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202333768A (zh) 2017-10-25 2023-09-01 美商健生醫藥公司 Tau胜肽之組成物及其用途
WO2020123492A1 (en) * 2018-12-10 2020-06-18 New York University Monoclonal antibodies targeting c-terminal region of phosphorylated tau
SG11202108312PA (en) 2019-02-08 2021-08-30 Ac Immune Sa Method of safe administration of phosphorylated tau peptide vaccine
MX2021012994A (es) * 2019-04-24 2022-03-04 Janssen Pharmaceuticals Inc Administracion heterologa de vacunas tau.
CN114341364B (zh) * 2019-07-08 2025-07-18 阿尔兹卡生物科学公司 Tau病理靶向配体
CN114728169A (zh) * 2019-09-23 2022-07-08 麦考瑞大学 tau蛋白病的治疗
US11744874B2 (en) 2019-12-20 2023-09-05 Nammi Therapeutics, Inc. Formulated and/or co-formulated liposome compositions containing toll-like receptor (“TLR”) agonist prodrugs useful in the treatment of cancer and methods thereof
CN115968291A (zh) * 2020-04-22 2023-04-14 南湖制药公司 聚乙二醇化干扰素tau及其组合物和方法
CN116472055A (zh) 2020-08-07 2023-07-21 欧萨尔普罗席纳有限公司 治疗阿尔兹海默氏病的多表位疫苗
WO2022054795A1 (ja) * 2020-09-08 2022-03-17 国立大学法人大阪大学 リン酸化タウタンパク質を標的とする免疫原性組成物
CA3192429A1 (en) * 2020-09-17 2022-03-24 Robin Barbour Alpha-synuclein vaccine for the treatment of synucleinopathies
KR20240042508A (ko) * 2021-08-12 2024-04-02 얀센 파마슈티칼즈, 인코포레이티드 지속적인 면역 반응을 유도하기 위한 인산화 타우 펩티드를 함유하는 리포솜
EP4408864A4 (en) * 2021-09-29 2025-09-03 Janssen Pharmaceuticals Inc METHOD FOR SAFE ADMINISTRATION OF A TAU PHOSPHOPEPTIDE CONJUGATE
IL314865A (en) * 2022-02-09 2024-10-01 Ac Immune Sa Anti-alpha-synuclein therapeutic vaccines
CA3261968A1 (en) * 2022-07-14 2024-01-18 Vaxxinity, Inc. IMMUNOGENEOUS TAU PEPTIDE CONSTRUCTIONS
AU2024367338A1 (en) * 2023-10-24 2026-04-30 Ac Immune Sa Method of treating preclinicial alzheimer's disease
WO2025109524A1 (en) 2023-11-22 2025-05-30 Ac Immune Sa Assays and methods for assessing vaccine preparations
KR102988842B1 (ko) 2024-10-22 2026-07-09 주식회사 엘지에너지솔루션 리튬 이차 전지용 음극, 리튬 이차 전지, 전지 모듈 및 전지 팩

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5811310A (en) 1986-09-30 1998-09-22 Albert Einstein College Of Medicine Of Yeshiva Univ. The Alz-50 monoclonal antibody and diagnostic assay for alzheimer's disease
WO1990014837A1 (en) 1989-05-25 1990-12-13 Chiron Corporation Adjuvant formulation comprising a submicron oil droplet emulsion
US7408027B1 (en) 1991-12-06 2008-08-05 Max-Planck-Gesellschaft Zur Forderung Der Wissenchaften Tools for the diagnosis and treatment of Alzheimer's disease
AU690092B2 (en) 1992-12-14 1998-04-23 N.V. Innogenetics S.A. Monoclonal antibodies directed against the microtubule-associated protein tau, hybridomas secreting these antibodies, antigen recognition by these monoclonal antibodies and their applications
US7427392B1 (en) 1994-11-14 2008-09-23 Elan Pharmaceuticals, Inc. Methods for aiding in the diagnosis of alzheimer's disease by measuring amyloid-β peptide (x-≧41) and tau
WO1997034145A1 (fr) 1996-03-13 1997-09-18 Mitsubishi Chemical Corporation Anticorps a proteine tau antiphosphorylee et procede de detection de la maladie d'alzheimer l'utilisant
WO1998022120A1 (en) 1996-11-19 1998-05-28 The Wistar Institute Of Anatomy & Biology Diagnostic and therapeutic reagents for alzheimer's disease
EA003739B1 (ru) 1997-12-03 2003-08-28 Байоджен, Инк. Гидрофобно-модифицированные белки, способы их получения и их применение
US6314469B1 (en) 1999-02-26 2001-11-06 I-Dns.Net International Pte Ltd Multi-language domain name service
AU2001273361A1 (en) 2000-07-11 2002-01-21 Molecular Geriatrics Corporation Reagents and methods for identification of binding agents
GB0114719D0 (en) 2001-06-15 2001-08-08 Glaxo Group Ltd Compound
AU2003203079B9 (en) 2002-02-04 2009-01-15 Oncothyreon Inc. Immunostimulatory, covalently lipidated oligonucleotides
KR100994748B1 (ko) 2002-04-19 2010-11-17 더 가버닝 카운실 오브 더 유니버시티 오브 토론토 알쯔하이머병의 치료를 위한 면역학적 방법 및 조성물
KR20050101537A (ko) 2002-12-24 2005-10-24 뉴로켐 (인터내셔널) 리미티드 베타-아밀로이드 관련 질환의 치료를 위한 치료 제제
US8663650B2 (en) 2003-02-21 2014-03-04 Ac Immune Sa Methods and compositions comprising supramolecular constructs
WO2005058137A2 (en) 2003-12-12 2005-06-30 University Of Washington Catheterscope 3d guidance and interface system
US20050261475A1 (en) 2004-02-13 2005-11-24 Harvard Medical School Solid-phase capture-release-tag methods for phosphoproteomic analyses
US7238788B2 (en) 2004-02-18 2007-07-03 University Of Iowa Foundation Antibodies to phosphorylated tau, methods of making and methods of use
WO2006121656A2 (en) 2005-05-05 2006-11-16 Merck & Co., Inc. Peptide conjugate compositions and methods for the prevention and treatment of alzheimer's disease
WO2007068105A1 (en) 2005-12-12 2007-06-21 Robarts Research Institute Method of diagnosing amyotrophic lateral sclerosis
CA2633399C (en) 2005-12-12 2016-01-26 Ac Immune S.A. Therapeutic vaccine
EP2514824A3 (en) 2006-03-03 2013-01-23 Amorfix Life Sciences Ltd. Methods and compositions to treat and detect misfolded-SOD1 mediated diseases
US8012936B2 (en) 2006-03-29 2011-09-06 New York University Tau fragments for immunotherapy
US20080220449A1 (en) 2007-02-08 2008-09-11 Oligomerix, Inc. Biomarkers and assays for Alzheimer's disease
KR20100115340A (ko) 2007-10-19 2010-10-27 이무나스 파마 가부시키가이샤 Aβ 올리고머에 특이적으로 결합하는 항체 및 그의 이용
US9498522B2 (en) 2008-08-07 2016-11-22 Mercia Pharma Inc. Immunotherapeutic compositions for the treatment of alzheimer'S disease
CN102365295A (zh) 2009-01-30 2012-02-29 阿德利夫股份有限公司 构象动力肽
US9605054B2 (en) 2009-02-23 2017-03-28 The Board Of Trustees Of The University Of Illinois Composition and method for treating a tauopathy
MX2011009654A (es) 2009-03-18 2011-10-12 Ac Immune Sa Metodo para uso terapeutico.
UA107571C2 (xx) 2009-04-03 2015-01-26 Фармацевтична композиція
EP4218794A3 (en) 2009-06-10 2023-09-13 New York University Immunological targeting of pathological tau proteins
CN102596236B (zh) 2009-07-30 2015-06-24 辉瑞疫苗有限责任公司 抗原性Tau肽及其用途
AU2010291933B2 (en) 2009-09-14 2016-09-08 Banyan Biomarkers, Inc. Micro-RNA, autoantibody and protein markers for diagnosis of neuronal injury
KR20130103662A (ko) 2010-04-19 2013-09-24 엔라이프 떼라퓨틱스, 에스.엘. 올리고뉴클레오티드 분자들의 특정 뉴런 유형들로의 선택적인 전달을 위한 조성물들 및 방법
WO2012020124A1 (en) 2010-08-12 2012-02-16 Ac Immune S.A. Vaccine engineering
EP2632434B1 (en) * 2010-10-26 2025-08-20 AC Immune S.A. Liposome-based construct comprising a peptide modified through hydrophobic moieties
GB201112056D0 (en) * 2011-07-14 2011-08-31 Univ Leuven Kath Antibodies
EP3275461A1 (en) * 2011-09-19 2018-01-31 Axon Neuroscience SE Protein-based therapy and diagnosis of tau-mediated pathology in alzheimer's disease field
CA2811188C (en) 2011-09-23 2020-04-28 Andrea Pfeifer Vaccine therapy
WO2013058350A1 (ja) 2011-10-21 2013-04-25 三菱化学株式会社 周期表第13族金属窒化物半導体結晶の製造方法、及び該製造方法により製造される周期表第13族金属窒化物半導体結晶
EP2659906A1 (en) 2012-05-01 2013-11-06 Affiris AG Compositions
US20140056901A1 (en) 2012-08-21 2014-02-27 The Institute For Molecular Medicine Anti-tau antibodies and compositions for and methods of making and using in treatment, diagnosis and monitoring of tauopathies
US20170368167A9 (en) * 2012-08-21 2017-12-28 The Institute For Molecular Medicine Compositions and methods related to neurological disorders
WO2014165271A2 (en) 2013-03-13 2014-10-09 Neotope Biosciences Limited Tau immunotherapy
CN105939722A (zh) 2014-02-14 2016-09-14 伊皮埃里安股份有限公司 Tau肽,抗Tau抗体,及其使用方法
CA2952741A1 (en) 2014-06-26 2015-12-30 Janssen Vaccines & Prevention B.V. Antibodies and antigen-binding fragments that specifically bind to microtubule-associated protein tau
NZ775762A (en) 2015-06-05 2025-02-28 Genentech Inc Anti-tau antibodies and methods of use
CA2988436A1 (en) 2015-07-13 2017-01-19 Arvinas, Inc. Alanine-based modulators of proteolysis and associated methods of use
EP4657376A3 (en) 2015-08-14 2026-03-04 Intuitive Surgical Operations, Inc. Systems and methods of registration for image-guided surgery
MX2018013384A (es) 2016-05-02 2019-02-28 Prothena Biosciences Ltd Anticuerpos que reconocen tau.
EP3551220B1 (en) 2016-12-07 2025-01-29 Genentech, Inc. Anti-tau antibodies and methods of use
TW202333768A (zh) * 2017-10-25 2023-09-01 美商健生醫藥公司 Tau胜肽之組成物及其用途
CN111587123A (zh) 2017-11-09 2020-08-25 品通治疗有限公司 用于生成和使用人源化构象特异性磷酸化的τ抗体的方法和组合物
SG11202108312PA (en) * 2019-02-08 2021-08-30 Ac Immune Sa Method of safe administration of phosphorylated tau peptide vaccine
MX2021012994A (es) 2019-04-24 2022-03-04 Janssen Pharmaceuticals Inc Administracion heterologa de vacunas tau.

Similar Documents

Publication Publication Date Title
IL273980B1 (en) Compositions of phosphorylated tau peptides and uses thereof
JP2022520060A5 (cg-RX-API-DMAC7.html)
JP2021501147A5 (cg-RX-API-DMAC7.html)
JP4280309B2 (ja) Dna免疫刺激配列活性の阻害剤
CN103747805B (zh) 用于治疗、延缓和/或预防人类遗传性疾病如强直性肌营养不良症1型(dm1)的化合物
US20060189550A1 (en) Immunostimulatory, Covalently lipidated oligonucleotides
US20040038922A1 (en) Vaccine composition
US20250275920A1 (en) Method of Safe Administration of Phosphorylated TAU Peptide Vaccine
JP5165681B2 (ja) タンパク質断片又はペプチドカクテルとして送達される抗原を用いたワクチン接種によるサブドミナントエピトープを含むt細胞レパートリーの拡大
US20230218730A1 (en) Vaccine therapy for ran protein diseases
WO1996013522A1 (en) Complementarily bonded two- and three-dimensional supramolecular structures
JP2022529529A5 (cg-RX-API-DMAC7.html)
JP2021517471A5 (cg-RX-API-DMAC7.html)
US20040009943A1 (en) Pathogen vaccines and methods for using the same
KR20220005033A (ko) 타우 백신의 이종 투여
EP2300494A1 (en) Anti-amyloid immunogenic compositions, methods and uses
JP2024534786A5 (cg-RX-API-DMAC7.html)
WO2012141280A1 (ja) Dnaワクチン
EP1265632A2 (en) Lipopeptide adjuvants
EP1505942B1 (en) Pathogen vaccines and methods for using the same
EP1292333B1 (fr) Composition adjuvante comprenant la proteine fha ou un fragment de la proteine fha sous forme libre
JP2024532787A5 (cg-RX-API-DMAC7.html)
KR20230106325A (ko) 핵산 복합체를 포함하는 퇴행성 뇌질환의 예방 또는 치료용 조성물
CA2204618A1 (fr) Proteine g du virus respiratoire syncytial exprimee sur membrane bacterienne
US20250144212A1 (en) Liposomes containing phosphorylated tau peptides for inducing sustained immune responses